Skin checks are an important tool in the early detection of skin cancers. MIA & others in the skin cancer community have advocated for a more systematic, targeted & equitable approach to skin cancer screening in Australia. As a result, the Australian Gov't has allocated $10m for development of a Roadmap for a National Targeted Skin Cancer Screening Program.
We were delighted to have the honour of meeting with His Majesty King Charles III this week, a once-in-a-lifetime opportunity to shine an international spotlight on melanoma.
MIA’s leading experts and early career researchers have shared the world stage at the annual European Society for Medical Oncology (ESMO) Congress in Barcelona.
MIA, alongside ACEMID, hosted an important melanoma data workshop in Sydney, to prepare for the massive volumes of data that will help create the evidence for a national targeted melanoma-screening program.
La Roche-Posay, the number one skincare brand recommended by dermatologists worldwide, and MIA, world leading melanoma research organisation, have embarked on a new five-year partnership to support critical melanoma research and accelerate awareness of sun safety.
Announcing a partnership between MIA and the Boating Industry Association (BIA) to promote sun safety amongst boating enthusiasts, including MIA hosting a stand at the Sydney International Boat Show in August.
Final results of the COMBI-AD clinical trial, published in New England Journal of Medicine, show significant benefit in preventing disease progression in BRAF positive Stage III melanoma patients.
Our 2024 Australians of the Year recently explored the Northern Territory, as part of a visit organised by the Australia Day Council. View the photo album.
Melanoma patients throughout the Riverina will benefit from strengthened melanoma services thanks to the newly opened MIA Amie St Clair clinic in Wagga, which includes a 3D full body imaging machine, clinic rooms and space for support groups and community events.
In what has been described as a cancer treatment revolution, the pre-surgery use of combination immunotherapy looks to become standard treatment for melanoma and impact other cancers across the globe.
